Glycine

Generic Name
Glycine
Brand Names
Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
Drug Type
Small Molecule
Chemical Formula
C2H5NO2
CAS Number
56-40-6
Unique Ingredient Identifier
TE7660XO1C
Background

A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

Indication

Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.

Associated Conditions
Coronary vascular graft occlusion, Deep Vein Thrombosis, Myocardial Infarction, Stroke, Transient Ischemic Attack, Vascular Occlusion
Associated Therapies
Bladder distension, Bladder irrigation therapy, Irrigation therapy, Recovery, Amino acid supplementation
Clinical Trials
Related News

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

First Posted Date
2012-11-02
Last Posted Date
2017-09-19
Lead Sponsor
Mclean Hospital
Target Recruit Count
2
Registration Number
NCT01720316
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

Phase 2
Terminated
Conditions
Herpes Labialis
Herpes Simplex Virus
First Posted Date
2009-06-04
Last Posted Date
2012-06-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
11
Registration Number
NCT00913692
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Adjunctive Glycine for Obsessive Compulsive Disorder

Not Applicable
Completed
Conditions
Obsessive Compulsive Disorder
Interventions
Other: placebo
Drug: glycine
First Posted Date
2006-11-30
Last Posted Date
2016-12-16
Lead Sponsor
Nathan Kline Institute for Psychiatric Research
Target Recruit Count
24
Registration Number
NCT00405535
Locations
🇺🇸

The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Phase 2
Completed
Conditions
Alcoholism
Schizophrenia
Interventions
Drug: placebo
Drug: Glycine
First Posted Date
2006-06-20
Last Posted Date
2018-01-17
Lead Sponsor
Yale University
Target Recruit Count
20
Registration Number
NCT00338598
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition

Phase 3
Withdrawn
Conditions
Diarrhea, Malnutrition
First Posted Date
2006-06-20
Last Posted Date
2008-10-28
Lead Sponsor
University of Virginia
Target Recruit Count
108
Registration Number
NCT00338221

Glycine vs Placebo for the Schizophrenia Prodrome

Phase 2
Completed
Conditions
Schizophrenia Prodrome
Interventions
Drug: Placebo
Drug: Glycine
First Posted Date
2006-02-13
Last Posted Date
2020-04-02
Lead Sponsor
Yale University
Target Recruit Count
8
Registration Number
NCT00291226
Locations
🇺🇸

PRIME Clinic, New Haven, Connecticut, United States

Glycine Treatment of Prodromal Symptoms

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: glycine
First Posted Date
2005-12-22
Last Posted Date
2012-03-29
Lead Sponsor
Yale University
Target Recruit Count
10
Registration Number
NCT00268749

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
First Posted Date
2005-09-22
Last Posted Date
2019-08-20
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
240
Registration Number
NCT00222235
Locations
🇺🇸

Maryland Psychiatric Research Center, Baltimore, Maryland, United States

🇮🇱

Ezrath Nashim Association, Sarah Herzog Memorial Hospital, Jerusalem, Israel

🇺🇸

UCLA/VA Greater Los Angeles Health Care System, Los Angeles, California, United States

and more 2 locations

Long-term Impact and Intervention for Diarrhea in Brazil

First Posted Date
2005-08-23
Last Posted Date
2011-03-08
Lead Sponsor
University of Virginia
Target Recruit Count
321
Registration Number
NCT00133406
Locations
🇧🇷

Federal University of Ceará, Fortaleza, Brazil

HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition

First Posted Date
2005-08-23
Last Posted Date
2008-10-28
Lead Sponsor
University of Virginia
Target Recruit Count
108
Registration Number
NCT00133562
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy